PELO inhibitors belong to a distinctive class of chemical compounds that are characterized by their ability to modulate the activity of the Pelota (PELO) protein. The Pelota protein plays a crucial role in the termination phase of protein synthesis during translation. Translation is a fundamental cellular process where genetic information encoded in mRNA molecules is deciphered by ribosomes to produce proteins. PELO, acting in coordination with the GTPase protein HBS1L, aids in the release of the nascent polypeptide chain from the ribosome, allowing the completion of translation. This termination step is essential for accurate protein synthesis and overall cellular homeostasis. PELO inhibitors typically function by binding to specific regions of the Pelota protein, interfering with its interaction with ribosomal complexes or other essential translation factors. By perturbing the PELO-mediated termination process, these inhibitors can lead to the accumulation of partially synthesized protein chains, disruption of ribosomal recycling, and potentially trigger cellular stress responses.
The structural diversity within the class of PELO inhibitors allows for the exploration of various binding modes and potential mechanisms of action. Researchers utilize this class of compounds as valuable tools in deciphering the intricate molecular mechanisms underlying translation termination, as well as in investigating the broader impact of modulating protein synthesis pathways. Due to their specific mode of action and their influence on translation termination, PELO inhibitors have gained significant attention in cell biology and molecular research. Understanding the complex interplay between translation factors and their regulators, such as PELO, can provide insights into the basic functioning of cells and contribute to our comprehension of various cellular processes. The development of potent and selective PELO inhibitors serves as a means to probe these mechanisms and uncover novel avenues for intervention in cellular activities, offering a promising avenue for advancing our knowledge of fundamental biology.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $105.00 | 3 | |
Inhibits 5-alpha-reductase, blocking conversion of testosterone to dihydrotestosterone (DHT), reducing DHT levels and affecting conditions like male pattern baldness. | ||||||
Minoxidil (U-10858) | 38304-91-5 | sc-200984 sc-200984A | 100 mg 1 g | $69.00 $351.00 | ||
Widens blood vessels, increasing blood flow to hair follicles, which may prolong the anagen (growth) phase of the hair cycle. | ||||||
Dutasteride | 164656-23-9 | sc-207600 | 10 mg | $167.00 | 2 | |
Blocks both Type I and Type II 5-alpha-reductase, resulting in a more comprehensive reduction of DHT levels. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Antifungal agent that may reduce DHT levels and inflammation in the scalp, promoting hair growth. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Stimulates hair follicles, promoting hair growth and potentially counteracting the effects of dihydrotestosterone. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Aldosterone antagonist that indirectly reduces DHT levels by blocking androgen receptors, commonly used in androgenic alopecia in women. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine receptor antagonist that may block DHT binding to hair follicles, potentially promoting hair growth. | ||||||
Azelaic acid | 123-99-9 | sc-257106 | 25 g | $42.00 | ||
Suppresses 5-alpha-reductase activity, leading to a decrease in DHT levels in the scalp. | ||||||